Combotope Therapeutics

Executive Summary

Combotope Therapeutics is a Danish biotechnology company founded in 2018 that is pioneering tumor-specific antibody therapeutics for oncology and immunology. The company's proprietary SMART-Phage™ discovery platform generates antibodies targeting Tn/STn glycan antigens, which are highly expressed on cancer cells but absent in healthy tissues. This approach aims to create therapies with exceptional specificity, reducing off-target toxicity compared to conventional antibody treatments. Although still in early stages, Combotope's technology holds promise for addressing unmet needs in solid tumors where Tn/STn antigens are prevalent.

Upcoming Catalysts (preview)

• H2 2026IND filing for lead antibody candidate40% success
• Q3 2026Preclinical proof-of-concept data publication60% success
• H1 2027Partnership or licensing deal for SMART-Phage platform30% success